---
schema_version: "secwatch.filing_event.v1"
accession: "0001023024-25-000024"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T12:50:46.400964+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ANI Pharmaceuticals buys out perpetual royalty on ILUVIEN/YUTIQ for $17.25M

## Summary
- Paid $17.25M one-time cash to SWK to eliminate 3.125% perpetual royalty on worldwide net revenues of ILUVIEN and YUTIQ.
- No further royalty due from January 1, 2025 forward; buyout covers all future net revenues.
- Funded with cash on hand; enhances financial flexibility for Retina portfolio growth.
- CEO Nikhil Lalwani states the transaction reflects commitment to maximizing long-term value of ILUVIEN and YUTIQ.

## SEC filing metadata
- accession: 0001023024-25-000024
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000024/0001023024-25-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000102302425000024/ani-20250318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001023024-25-000024
- JSON: https://secwatch.observer/filing/0001023024-25-000024.json
- Plain text: https://secwatch.observer/filing/0001023024-25-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.